Latest Breaking News On - நியூட்ரா பார்மா - Page 1 : vimarsana.com

Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures

Nutra Pharma Corporation: Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers

Nutra Pharma is announcing the first private label agreement in expansion of their line of over-the-counter pain relievers and anti-inflammatory drugs Plantation, Florida--(Newsfile Corp. - June 4, 2021)

Nutra Pharma Announces Influencer and Social Media Campaign for | The Kingston Whig Standard

Article content Plantation, Florida–(Newsfile Corp. – May 24, 2021) – Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today their plans for expanding the marketing of their over-the-counter pain relievers and anti-inflammatory products by working with influencers on several social media platforms. These will include celebrities as well as professional and Olympic athletes that have benefitted from Nutra Pharma’s products. We apologize, but this video has failed to load. Try refreshing your browser.

Nutra Pharma Corporation: Nutra Pharma is Excited to Announce: Luxury Feet now Available on Amazon

Nutra Pharma Explains How Technology Has Revolutionized the Pharmaceutical Industry

EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.

Nutra Pharma Corporation: Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials

Nutra Pharma Corporation: Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation in preparation of expanded OTC sales and clinical trials Plantation, Florida--(Newsfile Corp. - March 11, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on their work in improving their existing facilities for manufacturing and validation of their drug products; including their technologies for the treatment of Multiple Sclerosis (MS) and potential countermeasures against nerve agents like sarin gas and VX. As part of this process, Nutra Pharma today announces the engagement of AccuReg, Inc. as outside Regulatory and Quality Assurance consultants.

Global Oral Spray Market Insights, Overview, Analysis and Forecast 2021-2026

Nutra Pharma Corporation: Nutra Pharma Provides Updates on Laboratory Upgrades and Certifications

Nutra Pharma Corporation: Nutra Pharma Provides Updates on Laboratory Upgrades and Certifications Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation Plantation, Florida--(Newsfile Corp. - February 23, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on their work in improving their existing facilities for manufacturing and validation of their drug products, including their technologies as potential countermeasures against nerve agents like sarin gas and VX.

Nutra Pharma Corporation: Nutra Pharma Letter to Shareholders

Nutra Pharma Corporation: Nutra Pharma Letter to Shareholders Plantation, Florida--(Newsfile Corp. - January 12, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Letter to Shareholders on the Company's website. "The last year was a challenging one for all businesses but was certainly a very busy year at Nutra Pharma," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Regardless of the global pandemic and economic downturn, Nutra Pharma was able to create new opportunities for our products and technologies. This has provided a strong platform for real growth in 2021," he continued. "I wanted to take this opportunity to update our shareholders and the public on the accomplishments of the last year, the status of the Company and briefly outline our goals and expectations for the coming months," he concluded.